drugset / Trial / NCT05321251

Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.

NCT05321251

Phase 2/3 Withdrawn University of Alberta
RandomizedParallel-groupOpen-labelTreatment

Summary

Many diseases can affect corneal nerves. Corneas that lack normal sensation are considered neurotrophic. Neurotrophic corneas are predisposed to persistent epithelial defects, recurrent erosions, and corneal ulcers. These can lead to a variety of complications, from subjective pain, discomfort, and blurry vision, to corneal perforation and endophthalmitis. Neurotrophic corneas and the persistent epithelial defects associated with them can be very difficult to treat. Non-invasive measures include topical drops (artificial tears, antibiotics, or steroids), bandage contact lens, and punctal plugs. More invasive surgical treatments include membrane grafts, tarsorrhaphy, and keratoplasty. Despite these treatments, many neurotrophic corneas still do not heal. This study aims to test the efficacy of topical insulin in the treatment of neurotrophic keratopathy.

Timeline

Start
2022-06-01
Primary completion
2023-10-18
Completion
2023-10-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 25 unknown Topical